West Virginia MPJE (Pharmacy Jurisprudence) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the West Virginia MPJE Exam. Includes flashcards and multiple-choice questions, each with hints and explanations. Prepare effectively for your pharmacy law exam!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

When is an Investigational New Drug (IND) submitted to the FDA?

After Phase I trials
After Phase II trials
After preclinical animal research indicates a relatively safe drug with a potential therapeutic use
After Phase III trials

The correct answer is: After preclinical animal research indicates a relatively safe drug with a potential therapeutic use

An Investigational New Drug (IND) is not submitted to the FDA after Phase I, II, or III trials. It is typically submitted after preclinical animal research has been completed and indicates that the drug is relatively safe and has potential therapeutic use. This is because the IND application includes information about preclinical studies and their results. While Phase I, II, and III trials are important in the drug development process, they are primarily used to test the drug's safety and efficacy in humans. Therefore, the more accurate answer is C, after preclinical animal research is completed.